

General Services Fund Group

4A50 887605 Drug Law Enforcement

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$26,290	\$124,774	\$186,553	\$83,279	\$150,000	\$150,000
	374.6%	49.5%	-55.4%	80.1%	0.0%

Source: General Services Fund Group: State Board of Pharmacy's share of certain fines and bail or property forfeitures collected as a result of its drug law enforcement efforts

Legal Basis: ORC 4729.65(B)(1); Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A.

Purpose: This line item is used by the Board to provide its compliance and enforcement staff with current technology and training for the purpose of increasing their productivity and ability to obtain evidence of pharmacy and drug law violations. The fund's use is restricted to drug law enforcement purposes only.

4K90 887609 Operating Expenses

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$5,419,989	\$5,191,478	\$4,993,800	\$5,417,694	\$6,701,285	\$6,701,285
	-4.2%	-3.8%	8.5%	23.7%	0.0%

Source: General Services Fund Group: Money appropriated from the Occupational Licensing and Regulatory Fund (Fund 4K90), which consists of license fees and other assessments collected by certain independent professional and occupational boards, as well as various fines and forfeited bonds and bail collected by the State Board of Pharmacy and not credited to Fund 4A50

Legal Basis: ORC 4729.65(A); Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A. (originally established by Am. Sub. H.B. 152 of the 120th G.A.)

Purpose: This line item is used by the Board to administer and enforce laws governing the legal distribution of dangerous drugs and the practice of pharmacy.

Federal Special Revenue Fund Group

3BC0 887604 Dangerous Drugs Database

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$145,614	\$47,089	\$34,969	\$132,171	\$390,869	\$0
	-67.7%	-25.7%	278.0%	195.7%	-100%

Source: Federal Special Revenue Fund Group: CFDA 16.754, Harold Rogers Prescription Drug Monitoring Program grant (grant year 2011) distributed by the U.S. Department of Justice, Office of Justice Programs

Legal Basis: Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A. (originally established by Controlling Board on August 15, 2005)

Purpose: Money deposited to the credit of the fund consists of certain federal grants awarded to the State Board of Pharmacy for the purpose of planning, implementing, or enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th G.A. The program, known as the Ohio Automatic Rx Reporting System (OARRS), is a system in which prescription data for controlled substances, as well as two non-controlled substances, are submitted to a centralized database administered by the Board. It is designed for the purpose of helping prevent and detect the diversion and abuse of pharmaceutical controlled substances, particularly at the retail level. By law, the Board cannot impose a charge on any terminal distributor, pharmacist, or prescriber for establishment or maintenance of the database.

State Board of Pharmacy

3CT0 887606 2008 Developing/Enhancing PMP

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$260,211	\$79,398	\$17,270	\$45,000	\$224,691	\$112,346
	-69.5%	-78.2%	160.6%	399.3%	-50.0%

Source: Federal Special Revenue Fund Group: CFDA 93.748, Cooperative Agreements for Prescription Drug Monitoring Program Electronic Health Record (EHR) Integration and Interoperability Expansion, a grant distributed by the U.S. Department of Health and Human Services; prior \$400,000 grant from CFDA 16.580, Harold Rogers Prescription Drug Monitoring Program grant (grant year 2008) distributed by the U.S. Department of Justice, Office of Justice Programs closed out in FY 2012

Legal Basis: Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A. (originally established by Controlling Board on November 17, 2008)

Purpose: Money deposited to the credit of the fund currently consists of a \$449,382 federal grant awarded to the State Board of Pharmacy for the purpose of enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th G.A. The specific purpose of the grant is to: (1) expand the number of hospital sites and physician offices where prescribers are able to access OARRS information within their normal workflow, (2) implement access to OARRS reports from within pharmacy dispensing software, and (3) increase the number of states with which OARRS is able to share data. The prescription drug monitoring program is described in the preceding entry for Fund 3BC0, line item 887604, Dangerous Drugs Database.

3DV0 887607 Enhancing Ohio's PMP

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$0	\$161,092	\$238,908	\$0	\$2,000	\$2,000
	N/A	48.3%	-100%	N/A	0.0%

Source: Federal Special Revenue Fund Group: CFDA 16.754, Harold Rogers Prescription Drug Monitoring Program grant (grant year 2009) distributed by the U.S. Department of Justice, Office of Justice Programs

Legal Basis: Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A. (originally established by Controlling Board on August 24, 2009)

Purpose: Money deposited to the credit of the fund consists of a \$400,000 federal grant awarded to the State Board of Pharmacy for the purpose of enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th G.A. The program is described in the preceding entry for Fund 3BC0, line item 887604, Dangerous Drugs Database.

State Board of Pharmacy

3EB0 887608 NASPER

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$1,020	\$117,852	\$0	\$0	\$0	\$0
	11,458.5%	-100%	N/A	N/A	N/A

Source: Federal Special Revenue Fund Group: CFDA 93.975, National All Schedules Prescription Electronic Reporting (NASPER), a formula grant distributed by the U.S. Department of Health and Human Services (issued September 2009)

Legal Basis: Discontinued line item (originally established by Controlling Board on December 14, 2009)

Purpose: Money deposited to the credit of the fund consisted of a \$190,995 federal grant awarded to the State Board of Pharmacy for the purpose of enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th General Assembly. The program is described in the preceding entry for Fund 3BC0, line item 887604, Dangerous Drugs Database.

3EY0 887603 Administration of PMIX Hub

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$0	\$70,193	\$174,810	\$131,717	\$66,335	\$0
	N/A	149.0%	-24.7%	-49.6%	-100%

Source: Federal Special Revenue Fund Group: CFDA 16.754, Harold Rogers Prescription Drug Monitoring Program grant distributed by the U.S. Department of Justice, Office of Justice Programs

Legal Basis: Section 349.10 of Am. Sub. H.B. 59 of the 130th G.A. (originally established by Controlling Board on October 25, 2010)

Purpose: Money deposited to the credit of the fund consists of a \$386,973 federal grant awarded to the State Board of Pharmacy for the purpose of enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th G.A. The program is described in the preceding entry for Fund 3BC0, line item 887604, Dangerous Drugs Database.

State Board of Pharmacy

3EZ0 887610 NASPER 10

FY 2010 Actual	FY 2011 Actual	FY 2012 Actual	FY 2013 Actual	FY 2014 Appropriation	FY 2015 Appropriation
\$0	\$80,541	\$42,265	\$4,500	\$0	\$0
	N/A	-47.5%	-89.4%	-100%	N/A

Source: Federal Special Revenue Fund Group: CFDA 93.975, National All Schedules Prescription Electronic Reporting (NASPER), a formula grant distributed by the U.S. Department of Health and Human Services

Legal Basis: Discontinued line item (originally established by Controlling Board on October 25, 2010)

Purpose: Money deposited to the credit of the fund consisted of a \$191,452 federal grant awarded to the State Board of Pharmacy for the purpose of enhancing the prescription drug monitoring program authorized by Sub. H.B. 377 of the 125th General Assembly. The program is described in the preceding entry for Fund 3BC0, line item 887604, Dangerous Drugs Database.